溃疡性结肠炎中联合两种粪便检测的意义
日本全国性研究纳入879例溃疡性结肠炎(UC)患者,比较粪便钙卫蛋白(FCP)与粪便免疫化学血液检测(FIT)判断内镜严重程度及预测复发的准确性。FCP与FIT区分内镜活动度的曲线下面积无显著差异;FCP≥146 mg/kg(HR 4.83)与FIT≥77 ng/mL(HR 2.92)均独立关联12个月内临床复发,两者联合可识别缓解期高风险患者。
要点
- FCP与FIT区分MES≤1 vs MES≥2的AUC无显著差异(P=.394)。
- FCP≥146 mg/kg独立关联12个月内复发(HR 4.83,95%CI 2.80-8.33)。
- FCP与FIT联合可识别缓解期UC患者的复发风险。
核心结论
- FCP与FIT均可识别内镜疾病严重程度(MES≥2)的UC患者。
- 联合FCP与FIT结果可识别处于缓解期但有疾病复发风险的患者。
研究设计与样本
- 日本全国性研究,2015年3月至2017年3月纳入879例UC患者。
- 队列1(n=427)评估FCP与FIT判断临床严重程度(基于Mayo评分)及内镜缓解(基于MES或UC内镜严重指数)的诊断准确性。
- 队列2随访452例临床缓解的UC患者12个月,评估FCP水平与FIT结果与临床复发的关联。
主要发现
- FCP与FIT水平均与MES及UC内镜严重指数相关。
- FCP与FIT区分MES≤1 vs MES≥2的AUC无显著差异(P=.394),区分MES=0 vs MES≥1的AUC无显著差异(P=.178)。
- 基线临床缓解的405例患者中,38例(9.4%)3个月内复发,90例(22.2%)12个月内复发。
- FCP≥146 mg/kg(HR 4.83,95%CI 2.80-8.33)与FIT≥77 ng/mL(HR 2.92,95%CI 1.76-4.83)均独立关联12个月内临床复发。
- FCP≥146 mg/kg且FIT≥77 ng/mL者12个月内复发率69%,显著高于FCP≥146 mg/kg且FIT<77 ng/mL者(31.5%,P<.001)及FCP<146 mg/kg且FIT≥77 ng/mL者(30.0%,P<.001)。
关键数值与推荐
- FCP≥146 mg/kg:12个月内临床复发的HR 4.83(95%CI 2.80-8.33)。
- FIT≥77 ng/mL:12个月内临床复发的HR 2.92(95%CI 1.76-4.83)。
- FCP≥146 mg/kg且FIT≥77 ng/mL者12个月复发率69%,FCP≥146 mg/kg且FIT<77 ng/mL者31.5%(P<.001),FCP<146 mg/kg且FIT≥77 ng/mL者30.0%(P<.001)。
临床怎么用
- FCP与FIT均可用于识别内镜疾病严重程度(MES≥2)的UC患者。
- 联合FCP与FIT结果可识别缓解期UC患者中的复发高风险者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We compared the diagnostic accuracy of the fecal calprotectin (FCP) test vs the fecal immunochemical blood test (FIT) in determining the endoscopic severity and predicting outcomes of patients with ulcerative colitis (UC). METHODS: We performed a nationwide study of 879 patients with UC, enrolled at medical centers across Japan, from March 2015 to March 2017. We collected data on fecal biomarkers, endoscopic severities, and other clinical indices from Cohort 1 (n = 427) and assessed the diagnostic accuracy of FCP measurement and FIT results in determining clinical severity, based on Mayo score, and endoscopic remission, based on Mayo endoscopic sub-score (MES) or UC endoscopic index of severity. We also followed 452 patients in clinical remission from UC (Cohort 2) for 12 months and evaluated the associations of FCP levels and FIT results with clinical recurrence. RESULTS: The levels of FCP and FIT each correlated with the MES and UC endoscopic index of severity. There were no significant differences in the areas under the curve of FCP vs FIT in distinguishing patients with MES≤1 from those with MES≥2 (P = .394) or in distinguishing patients with MES=0 from those with MES≥1 (P = .178). Among 405 patients in clinical remission at baseline, 38 (9.4%) had UC recurrences within 3 months and 90 (22.2%) had recurrences within 12 months. FCP≥146 mg/kg (hazard ratio [HR], 4.83; 95% confidence interval [CI], 2.80-8.33) and FIT≥77 ng/mL (HR, 2.92; 95% CI, 1.76-4.83) were independently associated with clinical recurrence within 12 months. UC recurred within 12 months in 69% of patients with levels of FCP≥146 mg/kg and FIT ≥77 ng/mL; this value was significantly higher than the rate of recurrence in patients with levels of FCP≥146 mg/kg and FIT <77 ng/mL (31.5%, P < .001) or patients with levels of FCP<146 mg/kg and FIT ≥77 ng/mL (30.0%, P < .001). CONCLUSION: In a nationwide study of patients with UC in Japan, we found that the level of FCP and FIT could each identify patients with endoscopic markers of disease severity (MES≥2). The combination of FCP and FIT results can identify patients in remission who are at risk for disease recurrence. Clinical Trials Registry no: UMIN000017650 (http://www.umin.ac.jp/ctr/).
引用
- Naganuma M, Kobayashi T, Nasuno M, et al. Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019. PMID: 31394288. doi:10.1016/j.cgh.2019.07.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。